-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$30.00140.19% Upside
Mineralys Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Mineralys Therapeutics, Inc.?
Mineralys Therapeutics, Inc. has been rated by research analysts at Goldman Sachs in the past 90 days.